Broadly protective antibodies against coronaviruses

This project aims to improve and develop monoclonal antibodies (mAbs) for coronavirus protection, leveraging previous findings on non-neutralizing yet protective antibodies and engineered IgG subclasses.

It focuses on three main objectives: evaluating multimeric class-switched IgA and IgM mAbs, developing opsonic mAbs against SARS-CoV-2´s conserved E and M proteins, and engineering broadly functioning mAbs for protection against multiple coronaviruses.

The project enhances Fc-mediated effector functions through class switching and hinge engineering, exploring underutilized antibody classes beyond the industry-standard IgG1.

Targeting conserved protein structures and using antibody Fc effector functions rather than the normal focus on neutralization increases the likelihood of broad and long-lasting protection.

The project not only seeks to create a versatile antibody arsenal for future coronavirus outbreaks but also holds significant commercialization potential. This potential is further supported by an investor and collaborations for in vivo testing.

The expected outcomes include innovative, commercially viable antibodies to treat immunocompromised individuals and prepare for future coronavirus epidemics.

The project also has plans for further development through licensing or large-scale production, ensuring long-term financial viability.